Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2014
Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)
J Aparicio, P Maroto, X García Del Muro, et al.
ESMO Open
|
August 30, 2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
A Rodriguez-Vida, B P Valderrama, D Castellano, et al.
Physical Review Letters
|
April 6, 2019
Genuine 12-Qubit Entanglement on a Superconducting Quantum Processor
Ming Gong, Ming-Cheng Chen, Yarui Zheng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2016
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
S Faivre, P Niccoli, D Castellano, et al.
British Journal of Cancer
|
June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
M E Gore, C Szczylik, C Porta, et al.
ESMO Open
|
April 11, 2022
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
E Grande, T Alonso-Gordoa, O Reig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2010
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)
R Garcia-Carbonero, J Capdevila, G Crespo-Herrero, et al.
ESMO Open
|
December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J E Rosenberg, M D Galsky, T Powles, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2014
Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)
J Aparicio, P Maroto, X García Del Muro, et al.
ESMO Open
|
August 30, 2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
A Rodriguez-Vida, B P Valderrama, D Castellano, et al.
Physical Review Letters
|
April 6, 2019
Genuine 12-Qubit Entanglement on a Superconducting Quantum Processor
Ming Gong, Ming-Cheng Chen, Yarui Zheng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2016
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
S Faivre, P Niccoli, D Castellano, et al.
British Journal of Cancer
|
June 19, 2015
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
M E Gore, C Szczylik, C Porta, et al.
ESMO Open
|
April 11, 2022
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
E Grande, T Alonso-Gordoa, O Reig, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2010
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)
R Garcia-Carbonero, J Capdevila, G Crespo-Herrero, et al.
ESMO Open
|
December 6, 2024
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J E Rosenberg, M D Galsky, T Powles, et al.
Page
of 8